MetaVia Inc - Company Profile
Powered by 
All the sales intelligence you need on MetaVia Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MetaVia Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MetaVia Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MetaVia Inc (MetaVia), formerly NeuroBo Pharmaceuticals Inc, a subsidiary of Dong-A ST Co Ltd, is a biotechnology company. It develops innovative drugs for cardiometabolic diseases. The company's product pipeline includes DA-1241, a once-daily oral G-protein-coupled receptor 119 (GPR119) agonist currently in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and DA-1726, a novel dual oxyntomodulin (OXM) analog designed for once-a-week injection that acts as an agonist for both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). These products are designed to address liver inflammation, lipid metabolism, and glucose control, with potential applications in treating MASH and obesity. MetaVia collaborates with strategic partner Dong-A ST Co., Ltd., part of the Dong-A Socio Group, to leverage research and development expertise. It is also evaluating ANA001, an oral niclosamide formulation for moderate COVID-19; NB-01 for painful diabetic neuropathy (PDN); NB-02, which targets cognitive impairment; and Gemcabene, aimed at treating dyslipidemia. MetaVia is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 210, 545 Concord Avenue, Cambridge, Massachusetts, 02138
Website
metaviatx.com
Telephone
1 857 7029600
No of Employees
9
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MTVA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-121.3%
(2024 vs 2023)
Market Cap*
$7.4M
* As of and is in US$
MetaVia Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| DA-1241: Metabolic Dysfunction-Associated Steatohepatitis |
| DA-1726: Obesity |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Corporate Changes/Expansions | In November, the company changed its name to MetaVia Inc. |
| 2024 | Contracts/Agreements | In August, the company signed a joint research agreement, together with Dong-A ST Co. Ltd. and ImmunoForge, to develop a long-acting, once-monthly, formulation of DA-1726. |
| 2024 | Contracts/Agreements | In July, the company signed an exclusive license agreement, providing MThera Pharma Co Ltd with the rights to NB-01 for the treatment of painful diabetic neuropathy. |
Competitor Comparison
| Key Parameters | MetaVia Inc | AstraZeneca Plc | Intercept Pharmaceuticals Inc | MediciNova Inc | Altimmune Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Cambridge | Cambridge | Morristown | La Jolla | Gaithersburg |
| State/Province | Massachusetts | Cambridgeshire | New Jersey | California | Maryland |
| No. of Employees | 9 | 96,100 | 341 | 6 | 57 |
| Entity Type | Public | Public | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrew Koven | Chairman | Executive Board | 2021 | 68 |
| Hyung Heon Kim | President; Chief Executive Officer | Senior Management | 2023 | 47 |
| Marshall Woodworth | Chief Financial Officer | Senior Management | 2023 | 68 |
| Mi-Kyung Kim | Chief Scientific Officer | Senior Management | - | - |
| Robert Homolka | Senior Vice President - Clinical Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer